Search results
Author(s):
Suketu H Nanavati
,
Robert J Bulgarelli
,
Jose Vazquez-Tanus
,
et al
Added:
3 years ago
Heart rate variability (HRV) is considered to be a means of assessing autonomic function. However, HRV alone provides mixed measures of autonomic function1–11 and, as a result, cannot provide much insight into the autonomic involvement in arrhythmia.1,6,10 When HRV analysis is employed in conjunction with respiratory activity (RA) analysis, it has been shown to independently, simultaneously, and…
View more
Author(s):
Harriette Van Spall
,
Robert Mentz
Added:
1 year ago
AHA 22 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Robert J Mentz (Duke University of Medicine, US) to discuss the findings of the TRANSFORM-HF trial (NCT03296813).
This study aimed to compare the loop diuretics furosemide and torsemide in the treatment of patients with heart failure.Over 2800 patients were enrolled in the trial and were randomized…
View more
Author(s):
Stephen J Greene
Added:
10 months ago
ESC-HFA 23 — Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial (NCT03296813).
The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
Stay updated on the AHA 22 late-breaking data!
In this information packed episode of the View from the Thoraxcenter, hosts Dr Joost Daemen and Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL) analyse the data from 10 late-breaking trials presented at the Scientific Sessions.
What are the key take-aways from AHA 22? What are the most promising findings? How should we understand…
View more
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
In this dynamic late-breaking science preview Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) share their take on the most anticipated trials of the AHA Scientific Sessions.
What late-breaking trials should we look out for? Which results are likely to impact your practice? What are the considerations and challenges?
Trials covered in detail include:
37s:…
View more
Author(s):
Bernardo Cortese
Added:
4 months ago
TCT 23 - We are joined by Dr Bernardo Cortese (Ospedale Fate bene Fratelli, IT) for a concise and insightful summary of the late-breaking trials that are expected to have an impact on structural heart disease care.Trials covered in detail include:PARTNER 3Evolut Low RiskLIFE-BTKAGENT-IDETRANSFORM IRecorded remotely from Milano, 2023.Editor: Jordan RanceVideo Specialist: Dan Brent
View more
Robert Mentz
Job title: Cardiologist
Author
Author(s):
Aruna D Pradhan
,
Gurleen Kaur
Added:
1 year ago
AHA 22 - Dr Gurleen Kaur, Director of the CardioNerds Internship(Brigham and Women's Hospital, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr Aruna Pradhan (Brigham and Women's Hospital, US), study director of the PROMINENT trial (NCT03071692)on the late-breaking data from AHA 2022.
PROMINENT was a multicenter randomized trial aiming to…
View more
Author(s):
Rawan Amir
,
Paul Kalra
Added:
1 year ago
AHA 22 - Dr Rawan Amir, CardioNerds Fellow (Johns Hopkins Hospital, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr Paul Kalra (Portsmouth Hosp Univ NHS Trust, UK), investigator of the late-breaking IRONMAN trial (NCT02642562).
This randomised, open-label multicentre trial assessed the effectiveness of intravenous iron treatment compared to…
View more
HFA 2023: Late-Breaking Science Video Collection
Video Series